CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 111,039	$ 120,495
Short-term marketable securities	197,158	251,657
Trade receivables, net of allowances	76,920	59,786
Inventory	13,185	12,868
Prepaid expenses and other current assets	41,374	40,658
Total current assets	439,676	485,464
Strategic inventory	18,956	11,094
Operating lease right-of-use asset	6,860	4,583
Property and equipment, net	5,133	1,890
Long-term marketable securities	236,451	160,270
Other assets	2,946	5,153
Deferred tax assets, net	178,680	168,197
Total assets	888,702	836,651
Current liabilities:
Accounts payable	14,910	40,444
Accrued research and development expenses	21,628	33,954
Accrued and other liabilities	115,347	90,603
Short-term operating lease liability	1,917	1,084
Total current liabilities	153,802	166,085
Long-term operating lease liability	7,504	5,023
Long-term accrued government rebates	6,132	2,562
Long-term accrued income taxes	15,488	15,176
Total liabilities	182,926	188,846
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	142	140
Treasury stock	(998,013)	(966,586)
Additional paid-in capital	1,048,598	968,600
Accumulated other comprehensive income	436	2,264
Retained earnings	654,613	643,387
Total stockholders’ equity	705,776	647,805
Total liabilities and stockholders’ equity	$ 888,702	$ 836,651

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are associated with clinical research and related activities, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of clinical accrued liabilities (due within one year or within the normal operating cycle if longer).

No definition available.